Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B by Sarah Maylin et al.
Maylin et al. BMC Infectious Diseases  (2015) 15:154 
DOI 10.1186/s12879-015-0881-4RESEARCH ARTICLE Open AccessShort-term spontaneous fluctuations of HBV DNA
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Background: We evaluated the short-term spontaneous fluctuations of HBV DNA and HBsAg levels in Senegalese
patients with chronic infection with hepatitis B virus and normal ALT and determined factors related to these
fluctuations.
Method: A total of 87 patients with persistent normal ALT values were enrolled in the study. Serum samples
were obtained at three different visits, with an interval of 2 months (M0, M2, and M4), and without initiating
anti HBV treatment. Levels of HBV DNA, quantitative HBsAg, ALT and AST, genotyping and viral DNA mutations
were analyzed.
Results: Among the 87 patients, genotype E was predominant (75%). The median HBV DNA level was 2.9 log10
IU/mL [2.2-3.4], 2.7 log10 IU/mL [2.1-3.6] and 2.7 log10 IU/mL [2.1-3.4] at M0, M2 and M4, respectively. The values
ranged from <1.1 to 7 log10 IU/mL and 55 (63%) had HBV DNA fluctuations ≥ 0.5 log10 IU/mL between two
visits. Patients in whom HBV DNA fluctuated ≥0.5 log10 IU/mL between M0 and M2 also had significant
fluctuations between M2 and M4, while patients with stable HBV DNA between M0 and M2 showed a stable
viral load between M2 and M4. The only factor found to be associated with HBV DNA fluctuations ≥ 0.5 log10
IU/mL was a low BMI (<21 kg/ m2). HBsAg levels were not correlated with HBV DNA levels.
Conclusion: Sixty-three percent of the enrolled Senegalese population showed a large, short-term fluctuation
of HBV DNA levels. Such fluctuations may have an impact on therapeutic management, requiring closer
monitoring.
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Hepatitis B virus (HBV) infection is a global epidemic,
with more than 350 million of chronically infected car-
riers of the virus surface antigen (HBsAg) [1]. Without
treatment, 15 to 40% of those with chronic HBV infec-
tion will develop cirrhosis that can potentially lead to
hepatocellular carcinoma [2].
HBV is hyperendemic in Senegal, where the preva-
lence of chronic HBsAg carriage is about 15-20% in the* Correspondence: sarah.maylin@sls.aphp.fr
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unless otherwise stated.general population [3]. Senegalese patients are primarily
infected during early childhood, and genotypes E and
A predominate in these infections. HBV infection in
Senegal shows an 83% rate of precore mutations [4].
Reliable, easy-to-perform markers are needed to assess
the impact of chronic HBV infection on liver diseases.
Quantification of plasma HBV DNA by real-time PCR,
combined with liver biopsy histo-pathological stage and
biological markers of hepatocyte cytolysis level, can dis-
tinguish inactive HBsAg carriers from patients with ac-
tive disease who require treatment. Patients should be
considered for treatment when they have HBV DNA
levels above 2000 IU/mL (3.2 log10 IU/mL), or serum
alanine aminotransferase (ALT) levels above the upperThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nificant fibrosis (≥F2) [5]. In developing countries, viral
load measurement is rarely accessible. If only one meas-
ure of viral load is available, it may not reflect real viral
activity. Possible fluctuations may affect the indication of
treatment. However, several studies have shown long-
term HBV DNA spontaneous fluctuations [6,7]. The
magnitude of these changes is likely to change a treat-
ment decision [7]. Short-term fluctuations and factors
affecting them remain unknown [8].
Recently, HBsAg levels have been proposed as a marker
for monitoring HBV infected patients [9,10]. HBsAg levels
change over the natural course of chronic HBV infection
and during antiviral therapy. Moreover, HBsAg quantifica-
tion can be used to differentiate true inactive carriers with
HBsAg level <1000 IU/mL from patients in remission
who are likely to progress to cirrhosis [11]. The aim of this
work is to describe spontaneous HBV DNA and HBsAg
level fluctuations over a four month- follow-up period
among Senegalese patients positive for HBsAg with nor-




Patients were consecutively enrolled by private practitioners
and by four public hospitals in Dakar, Senegal’s capital city,
from September 2005 to April 2006. Treatment-naive
patients above 18 years old, with positive HBsAg over
six months, symptom-free, HIV, HCV and HDV nega-
tive, were eligible for enrolment.
Eighty-seven patients with persistent normal ALT
values were prospectively monitored for determination
of ALT and aspartate aminotransferase (AST), quantifi-
cation of HBV DNA three times at two-month intervals
(M0, M2, and M4). For those with positive HBV DNA,
genotyping and mutations affecting the expression of
HBeAg were performed.
Ethical approvals
The protocol was in accordance with Declaration of
Helsinki ethical guidelines and was approved by the
Senegalese Health Research National Council. Patients
fulfilling the inclusion criteria were enrolled after provid-
ing written and informed consent. Lamivudine was pro-




The following data were collected [1]: general characteris-
tics (age, sex, weight, height, known HBV infection dur-
ation, body mass index (BMI)) [2]; biological markers at
the inclusion (genotype, HBeAg, HBsAg and platelets).HBV DNA, HBsAg quantification, ALT, AST, were mea-
sured three times with intervals of two months (M0, M2
and M4). ALT and AST results were expressed relative to
the normal values according to the technique used (Ortho
Clinical Diagnostics, Issy-les-Moulineaux, France) i.e.
52 IU/mL (females) and 72 IU/mL (males) for ALT,
and 36 IU/mL (females) and 59 IU/mL (males) for
AST. Variations of ALT, AST, HBsAg and HBV DNA
between two visits were determined and expressed as
ΔALT, ΔAST, ΔHBsAg and ΔHBV DNA, respectively.
Biological markers
HBeAg and qualitative HBsAg were performed by an au-
tomated EIA method (Axsym, Abbott Diagnostics, Rungis,
France). Biochemical parameters were determined by
Vitros 250 instrument (Ortho Clinical Diagnostics, Issy-
les-Moulineaux, France). Platelets were determined by
Cell-Dyn 3700 (Abbott).
Virological analyses
The HBV DNA quantification was performed using the
Cobas AmpliPrep/Cobas Taqman HBV test, v1.0 assay
(Roche Diagnostics, Meylan, France), with a detection
threshold of 12 IU/mL (1.1 log10 IU /mL).
The core mutation W28 at nucleotide 1896 (precore
mutation C28) and clade genotyping were determined by
research DNA microarray (bioMérieux, Marcy l’Etoile,
France) [12].
HBsAg quantification
Serum HBsAg levels were retrospectively quantified
using sera stored at −20 °C, which had been used for
HBV DNA measurement. Architect HBsAg EIA (Abbott,
Rungis, France) [13] was used with a dynamic range of
0.05-250 IU/mL. Samples with HBsAg >250 IU/mL were
diluted to 1/100 to bring the value within the range of
calibration [14].
Statistical analysis
Continuous variables were expressed as median and
interquartile ranges (IQR), and categorical variables were
expressed as percentages. Univariate analyses were based
on Fisher’s exact test for categorical variables and
Mann–Whitney test for continuous variables. The
HBsAg (log10 IU/mL) to HBV DNA (log10 IU/mL) ratio
was assessed for all serum samples according to HBV
DNA levels (≤3,]3–4],]4–5], and > 5 log10 IU/mL).
Comparison of ratios between levels of HBV replication
was analyzed with the Kruskal-Wallis non-parametric test.
When a significant difference was detected, Mann–
Whitney test was performed, with Bonferroni correction
for multiple testing. HBsAg and HBV DNA fluctuations
were measured three times at two month intervals (M0,
M2 and M4). For each subject, the largest difference in
Table 2 HBsAg and HBV DNA levels in the 87 subjects at
M0, M2 and M4
Variables N(%) Median [IQR]
HBV-DNA log10 IU/mL
- First sample 2.9 [2.2-3.4]
- Second sample 2.7 [2.1-3.6]
- Third sample 2.7 [2.1-3.4]
ΔHBV-DNA log10 between 2 visits
- ≤0.5 32 (37)
-]0.5-1] 31 (36)
-]1-2] 16 (18)
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recorded and classified according to four classes: ≤ 0.5,]
0.5-1][,]1-2] and >2 log10 IU/mL. Friedman’s test was used
to compare HBsAg fluctuations between the three values.
Correlation between viral load fluctuations was based on
the Spearman coefficient.
All variables associated with HBV DNA fluctuations > 0.5
log10 IU/mL in univariate analysis (p < 0.25) were included
in a backward stepwise logistic regression model. A P value
of ≤0.05 was considered to denote statistical significance.
Statistical analyses were performed using STATA software
version 12.0 (Stata Corporation, College Station, TX).- >2 8 (9)
HBV-DNA log10
- <3.2 log10 for all the visits 36 (41)
- ≥3.2 log10 for 1 or 2 visits 36 (41)
- ≥3.2 log10 for all the visits 15 (17)
HBsAg IU/mL,
- First sample 4672 [1473–8355]
- Second sample 4546 [1749–8871]
- Third sample 3473 [1241–8765]Results
Population characteristics
The characteristics of the studied population are summa-
rized in Table 1. The population was primarily male
(72%), with a median age of 30 years and a median BMI of
21 kg/m2. All patients maintained normal ALT, with a me-
dian of 0.5xULN (upper limit of normal) [0.4-0.6] over the
three visits. Genotype E was predominant (75%), the
remaining belonging to genotype A. The median HBV
DNA level was 2.9, 2.7 and 2.7 log10 IU/mL for the first,
second and third visits, respectively (Table 2). The values
ranged between <1.1 (undetectable) and 7 log10 IU/mL.
Thirty-six subjects (41%) had at least one visit with a
viral load ≥3.2 log10 IU/mL. Only 15 patients (17%) were
above ≥3.2 log10IU/mL and five patients (6%) had an
undetectable HBV DNA (<1.1 log10 IU/mL) throughout
the three visits.
Ninety percent of patients had a detectable viral load
at baseline (M0) and among them, two patients (5%) had
a positive HBeAg. Ninety four percent of patients had at
least one visit with detectable viral load, while 6% were
always undetectable (<1.1 log) over all the visits.Table 1 Characteristics of the 87 subjects
Variables N (%) Median [IQR]
Age (years) 30 [25–38]
Gender (males) 63 (72)
BMI (kg/m2) 21 [19-24]
- ALT(xULN*) 0.5 [0.4-0.6]
- AST (xULN*) 0.5 [0.4-0.7]
Platelets (giga/L) 194 [163–245]
Precore (W28) mutation (n = 62)
- Wild type 35 (56)
- Mutation 27 (44)
HBV Genotype (n = 63)
- A 16 (25)
- E 47 (75)
*ULN: upper limit of normal.Viral load fluctuations
Sixty-three percent of subjects (n = 55) experienced a
change in viral load of at least 0.5 log10 IU/mL between
two visits. In 8 patients (9%) the difference was >2 log10
IU/mL (max 2.8 log10 of difference) (Table 2). Intra-
individual changes over time in viral load based on fluc-
tuation ranges are represented in the figures as spaghetti
plots (Figures 1 and 2).
The only factor associated with a change in the viral
load > 0.5 log was BMI < 21 kg/m2 (OR: 3.5; 95% CI,
1.3-9.0) (Table 3).
Patients in whom HBV DNA fluctuated >0.5 log10
IU/mL between M0 and M2 also showed significant
fluctuation between M2 and M4 (positive correlation
r = 0.34, p = 0.005) (Figure 3), while patients with stable
HBV DNA between M0 and M2 showed a stable viral
load between M2 and M4 (Figure 4). Such significant fluc-
tuations were only observed in patients with genotype E
viruses (positive correlation r = 0.42, p = 0.05). For 45% of
the patients, the largest variation observed between two
samples was between the second and third samples.
HBsAg fluctuations
The values of HBsAg differed significantly between the
three visits (p = 0.03), mainly due to the difference observed
between the second and third samples, with respective
medians of 4546 and 3473 IU/mL (Table 2).
We did not find a link between HBsAg fluctuations
and a change in the viral load > 0.5 log10 IU/mL (Table 3).
There is no significant difference in HBsAg levels,
Figure 1 Viral load fluctuations between M0 and M4 in patients with a change in viral load ≥ 1 log10 IU/mL (n = 19)) (x axis = months;
y axis = viral load fluctuations (log10 IU/ml).
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precore mutation C28 (Table 4). The median HBsAg
level in patients with HBeAg negative was 6612 [1879–
9260], 6228 [1905–9089) and 5393 [2269–9883] IU/mL
for the first, second and third samples, respectively. The
HBsAg level was 7584 and 8765 IU/mL for the second
and third samples for the sole patient with positive
HBeAg.
HBsAg/HBV DNA ratio
The median HBsAg (log10 IU/mL) to HBV DNA (log10
IU/mL) ratio was significantly higher in samples withFigure 2 Viral load fluctuations between M0 and M4 in patients with
y axis = viral load fluctuations with a change <1 log10 IU/ml).HBV DNA values ≤3 log10 IU/mL (1.48 [1.24-1.73]),
compared to high HBV DNA values (1.04 [0.91-1.15]
for]3-4] log10 IU/mL (p < 0.001), 0.94 [0.67-0.95] for]4-5]
log10 IU/mL (p = 0.05) and 0.63 [0.58-0.67] for more
than 5 log10 IU/mL, (p < 0.001)) (Figure 5).
Discussion
This study highlights the frequency and magnitude of
spontaneous HBV DNA fluctuations over a short period
(4 months) among Senegalese patients with normal
transaminases, as well as their possible impact on clin-
ical characterization of the disease and its therapeutica change in viral load < 1 log10 IU/mL (n = 17) (x axis =months;
Table 3 Factors associated with fluctuation of HBV DNA greater than 0.5 log10 IU/mL
Variables – N (%) Patients with a change in viral load between two samples p value
≤0.5 log10 IU/mL (n = 32) >0.5 log10 IU/mL (n = 55)
Gender (males) 23 (72) 40 (73) 0.93
Age≥ 30 yrs 22 (69) 26 (47) 0.052
BMI < 21 (kg/m2) 10 (31) 32 (62) 0.007
Platelets (giga/L)* 188 [168–214] 209 [161–247] 0.94
ΔALT* 3 [1-8] 5 [3-9] 0.19
ΔAST* 2 [1-6] 4 [2-7] 0.075
ΔHBsAg* (n = 51) 924 [355–1248] 627 [218–1479] 0.99
Genotype E (n = 63) 15 (79) 32 (73) 0.60
Precore mutation C28 (n = 62)
- Wild type 9 (50) 16 (36) 0.32
- Mutation 9 (50) 28 (64)
*median [IQR].
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tuations and demographic parameters (age, gender) or
biochemical (transaminases) or virological data (genotype,
mutations affecting the expression of HBeAg) could be ex-
plained by a lack of power because of the small number of
subjects included in the study. Low BMI < 21 kg/m2 was
the only factor associated with HBV DNA fluctuations;
patients with a lower BMI values were at higher risk of
having fluctuations. One hypothesis is that HBV DNA
fluctuations can reflect more efficient immune response
which is more present in healthy, low BMI patients.
As previously demonstrated, there is strong evidence
that excess adiposity, defined by high BMI, negativelyFigure 3 Viral load fluctuation (log10 IU/mL) between the second and th
the first and second sample was >0.5 log10 IU/mL (x axis = viral load f
(log10 IU/mL); y axis = viral load fluctuations between the second and thimpacts immune function and host defenses in obese
individuals [15].
The stability of the biochemical markers contrasts with
the volatility of the HBV DNA.
The lower replicativity among HBeAg negative pa-
tients does not explain the HBV DNA variability ob-
served in our study.
The frequency and magnitude of DNA fluctuations
and their possible impact on clinical characterization of
the disease and its therapeutic management must be em-
phasized. Guidelines recommend that to be eligible for
treatment, patients must have a viral load greater than
or equal to HBV DNA 3.2 log IU/mL. Only 17% of ourird samples in patients for whom viral load fluctuation between
luctuations between the first and second sample (M0 et M2)
ird sample (M2 et M4) (log10 IU/mL).
Figure 4 Viral load fluctuation between the second and third samples in patients for whom viral load fluctuation between the first
and second sample was ≤0.5 log10 IU/mL. (x axis = viral load fluctuations between the first and second sample (M0 et M2) (log10 IU/mL); y axis
= viral load fluctuations between the second and third sample (M2 et M4) (log10 IU/mL).
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samples tested (M0, M2 and M4). Forty-two percent of
patients would have been eligible or ineligible for treat-
ment according to the viral load value at a given time. It
therefore seems necessary to measure viral load for mul-
tiple occasions before deciding to treat.
More recently, studies have reported that the manage-
ment of chronic hepatitis B can be optimized with
HBsAg quantification, used as a biomarker for stratifying
the risk of disease progression [16] and for predicting
treatment response mainly in patients receiving pegy-
lated interferon (PEG-IFN) therapy [17].
In clinical practice, HBsAg quantification cannot replace
viral load measurement. Combining both measures has
been shown to be important for monitoring the natural
history of the disease and treatment outcome [11]. We ob-
served a significant reduction in the HBsAg level between
the second and third visits. Consistent with other studies,Table 4 Fluctuations of HBsAg levels
Variables – Median (IQR) HBsAg levels*
(1st sample)
Genotype (n = 43)
- E 5648 (1914–10404)
- A 6429 (618–9134)
Precore mutation C28 in negative HBeAg patients
Wild type (n = 13) 7058 (1473–8355)
Mutation + (n = 14) 6906 (2964–12711)
*IU/mL.we found no correlation between HBV DNA levels and
HBsAg in these HBeAg-negative patients [18]. It has been
shown that the HBsAg / HBV DNA ratio, which reflects
the association between HBsAg production and HBV rep-
lication, increased after seroconversion without any HBsAg
level modification. Confirming immune control over viral
replication was the first step of immune clearance. This ra-
tio has been shown to be higher during the low-replicative
phase, compared to immune-tolerant, immune-clearance
and HBeAg negative hepatitis phase and to be repeatable
regardless to ethnicity or genotype [19-21]. Nevertheless,
in our study, the HBsAg / HBV DNA ratio was higher in
samples with low HBV DNA values than in those with
high HBV DNA values, as reported by others [22]. These
results suggest that the production of HBsAg is more con-
served than the HBV DNA replication indicating that the
association between HBsAg production and HBV DNA






5545 (2571–9876) 4486 (2611–9624)
6228 (635–8871) 4943 (610–9896)
0.26 0.56 0.56
6228 (1556–8871) 4943 (1241–9883)
7954 (3170–10389) 6874 (2952–10703)
Figure 5 Plots of log10 IU/ml HBsAg /HBV-DNA ratio by levels of HBV replication. (all samples) (x axis = BV DNA levels (log10 IU/mL);
y axis = HBsAg /HBV-DNA ratio).
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Since HBeAg-negative patients with higher HBsAg levels
were more susceptible to developing active disease,
quantification of HBsAg in such patients merits further
investigation.
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